Neoplasm Malignant clinical trials

Explore recruiting neoplasm malignant clinical trials.

Recruiting neoplasm malignant studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neoplasm Malignant trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) with Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)

France, Italy, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

France, Spain, Sweden, Germany, Italy, Belgium +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)

Norway, Spain, Sweden, Italy, Denmark, France +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants with Advanced Solid Tumors

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

First-in-human (FIH) Study of DS-1471a in Subjects with Advanced Solid Tumors

Belgium, Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Neoplasm Malignant trials by city

Neoplasm Malignant in Toronto Neoplasm Malignant in Vancouver Neoplasm Malignant in Montreal Neoplasm Malignant in Calgary Neoplasm Malignant in Edmonton Neoplasm Malignant in Ottawa Neoplasm Malignant in Winnipeg Neoplasm Malignant in Quebec City Neoplasm Malignant in Hamilton Neoplasm Malignant in Kitchener Neoplasm Malignant in London Neoplasm Malignant in Halifax Neoplasm Malignant in New York Neoplasm Malignant in Los Angeles Neoplasm Malignant in Chicago Neoplasm Malignant in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease